Gyurcsik Z, Bodnár N, Szekanecz Z, Szántó S
Department of Physiotherapy, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary.
Z Rheumatol. 2013 Dec;72(10):997-1004. doi: 10.1007/s00393-013-1240-8.
Biologics are highly effective in ankylosing spondylitis (AS). In this self-controlled study, we assessed the additive value of complex physiotherapy in decreasing chest pain and tenderness and improving respiratory function in AS patients treated with tumor necrosis factor α (TNF-α) inhibitors.
The trial consisted of 2 parts. In study I, clinical data of AS patients with (n=55) or without biological therapy (n=20) were retrospectively analyzed and compared. Anthropometrical data, duration since diagnosis and patient assessment of disease activity, pain intensity, tender points, sacroiliac joint involvement determined by X-ray, functional condition, and physical activity level were recorded. Subjective, functional, and physical tests were performed. In study II, 10 voluntary patients (6 men and 4 women, age 52.4 ± 13.6 years) with definite AS and receiving anti-TNF therapy were recruited. It was a prospective, non-randomized physiotherapeutic trial. BASFI (Bath Ankylosing Spondylitis Functional Index), BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), modified Schober Index, occiput-to-wall distance, and fingertip-to-floor distance were evaluated. Forced vital capacity, forced 1-s expiratory volume, peak expiratory flow, and maximum voluntary ventilation were recorded. Furthermore, typical tender points were recorded. A targeted physiotherapy program was conducted twice a week for 12 weeks and all above parameters were recorded at baseline and after 12 weeks.
Differences in patient assessment of disease activity (p=0.019) and pain intensity (p=0.017) were found in study I. Pain and tenderness of the thoracic spine were observed in both groups. Back pain without biologic therapy was slightly higher than other group. In study II, we found that patient assessment of disease activity and pain intensity significantly improved after the physical therapy program (p=0.002 and p<0.001). BASFI and BASDAI increased after treatment (p=0.004 and p<0.001). The finger-to-floor distance, chest expansion, and modified Schober index increased (p=0.008, p<0.001, and p=0.031, respectively). The respiratory functional parameters showed a tendency towards improvement.
AS patients already receiving biological therapy may benefit from additional targeted physiotherapy. Physical therapy may be of important additive value in AS patients being treated with biological. The exercise program presented here showed an improvement in functional parameters as well as spine and chest mobility, thereby enhancing the favorable effects of biological therapy.
生物制剂在强直性脊柱炎(AS)治疗中疗效显著。在这项自我对照研究中,我们评估了综合物理治疗对接受肿瘤坏死因子α(TNF-α)抑制剂治疗的AS患者在减轻胸痛和压痛以及改善呼吸功能方面的附加价值。
该试验包括两个部分。在研究I中,对接受(n = 55)或未接受生物治疗(n = 20)的AS患者的临床数据进行回顾性分析和比较。记录人体测量数据、诊断后的病程以及患者对疾病活动度、疼痛强度、压痛点、X线确定的骶髂关节受累情况、功能状况和身体活动水平的评估。进行主观、功能和体格检查。在研究II中,招募了10名确诊为AS且正在接受抗TNF治疗的自愿患者(6名男性和4名女性,年龄52.4±13.6岁)。这是一项前瞻性、非随机的物理治疗试验。评估巴斯强直性脊柱炎功能指数(BASFI)、巴斯强直性脊柱炎疾病活动指数(BASDAI)、改良Schober指数、枕墙距和指尖距地距离。记录用力肺活量、用力呼气1秒量、呼气峰值流速和最大自主通气量。此外,记录典型压痛点。每周进行两次针对性的物理治疗方案,为期12周,并在基线和12周后记录所有上述参数。
在研究I中发现患者对疾病活动度(p = 0.019)和疼痛强度(p = 0.017)的评估存在差异。两组均观察到胸椎疼痛和压痛。未接受生物治疗的背痛略高于另一组。在研究II中,我们发现物理治疗方案后患者对疾病活动度和疼痛强度的评估显著改善(p = 0.002和p < 0.001)。治疗后BASFI和BASDAI升高(p = 0.004和p < 0.001)。指尖距地距离、胸廓扩张度和改良Schober指数增加(分别为p = 0.008、p < 0.001和p = 0.031)。呼吸功能参数有改善趋势。
已接受生物治疗的AS患者可能从额外的针对性物理治疗中获益。物理治疗在接受生物治疗的AS患者中可能具有重要的附加价值。此处介绍的运动方案显示功能参数以及脊柱和胸廓活动度有所改善,从而增强了生物治疗的有益效果。